Skip to main content

Table 3 Persistence on index treatment among Medicaid beneficiaries newly prescribed ART

From: Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries

Persistence assessment

Number of days on therapy

Patients with 12-month persistence among those with 12 months follow-up

Patients with discontinuation of first-line therapyb

Median

N (%)

N (%)

All Regimens (STR + MTR) [N = 2409]

156.0

410 (43.2%)

953 (39.6%)

STRs [N = 1782]

166.0

313 (45.0%)

647 (36.31%)

 EVG/COBI/FTC/TAF [N = 274]

145.0

8 (100.0%)†

32 (11.7%)

 EVG/COBI/FTC/TDF [N = 475]

198.0

111 (43.4%)

224 (47.2%)

 ABC/3TC/DTG [N = 522]

180.0

106 (53.3%)

152 (21.6%)

 RPV/FTC/TAF [N = 27]

131.0

N/Aa

0 (0.0%)

 RPV/FTC/TDF [N = 196]

158.5

37 (38.9%)

92 (46.9%)

 EFV/FTC/TDF [N = 288]

140.0

51 (37.2%)

147 (51.0%)

MTRs [N = 627]

128.0

97 (38.0%)

306 (48.8%)

 ABC/3TC + DRV/r [N = 12]

146.0

2 (50.0%)

3 (25.0%)

 FTC/TDF + DTG [N = 205]

151.0

32 (47.8%)

92 (44.9%)

 FTC/TAF + DTG [N = 31]

79.0

N/Aa

0 (0.0%)

 FTC/TDF + DRV/r [N = 184]

119.0

34 (33.3%)

110 (59.8%)

 FTC/TDF + DRV/c [N = 50]

144.0

4 (30.8%)

25 (50.0%)

 FTC/TDF + ATV/r [N = 121]

120.0

25 (37.3%)

71 (58.7%)

  1. MTRs including ABC/3TC + DRV/c, FTC/TAF/r/c, FTC/TDF + ATV/c, and FTC/TAF + ATV/r/c were not examined due to the limited sample size
  2. 3TC lamivudine, ABC abacavir, ATV atazanavir, ATV/c atazanavir boosted with cobicistat, ATV/r atazanavir boosted with ritonavir, COBI cobicistat, DRV darunavir, DRV/r darunavir boosted with ritonavir, DRV/c darunavir boosted with cobicistat, DTG dolutegravir, EFV efavirenz, EVG elvitegravir, FTC emtricitabine, MTR multi-tablet regimen, RPV rilpivirine, STR single tablet regimen, TAF tenofovir alafenamide fumarate, TDF tenofovir disoproxil fumarate
  3. aEVG/COBI/FTC/TAF was approved by the FDA in November 2015, RPV/FTC/TAF was approved March 2016, and FTC/TAF was approved April 2016, thus limiting the number of patients with 12 months of follow-up
  4. bAge groups (18–34 years, 35–49 years, 50–64 years and ≥ 65 years), gender (female and male), race (White, Black, Hispanic and other), insurance type (HMO and COMP), baseline clinical comorbidities (central nervous system toxicity, gastrointestinal symptoms, mental disorders, AIDS-defining condition, substance abuse, jaundice, dyslipidemia, diabetes, chronic kidney disease, cardiovascular disease and myocardial infarction), pre index medication use (antihypertensive, antidiabetics, anticoagulants, antiarrhythmic drugs, lipid-lowering therapy, antibiotics and respiratory drugs), number of unique medications on index date other than antiretroviral therapy (ART), and Deyo-modified CCI score
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us